Results From Multi-Dose Vorinostat Trial
Selected Research Highlight From CROI 2013
March 25, 2013
Sharon Lewin from Monash University in Melbourne debuted data from the first multidose trial of vorinostat (also known as SAHA) as a potential anti-HIV latency drug (abstract, webcast -- ninth in session). Consistent with results published by David Margolis from a single-dose trial, expression of HIV RNA significantly increased among the twenty participants after 14 days of vorinostat. However, there was no evidence for reduction in the size of the latent HIV reservoir, suggesting that additional approaches will be needed to facilitate the elimination of the infected cells. As expected, vorinostat side effects were more prevalent as a result of the multiple dosing, particularly fatigue and lethargy.
Richard Jefferys is the coordinator of the Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog at the Treatment Action Group (TAG). The original blog post may be viewed here.
CROI 2013: The Latest on HIV Drugs in Development, Antiretroviral Strategy and Treatment as Prevention (Video)
This article was provided by Treatment Action Group. It is a part of the publication Michael Palm HIV Basic Science, Vaccines & Cure Project.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)